Internal Medicine, Hematology & Oncology · Smithtown, NY
NPI
1154300622
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
48 Route 25a Ste 209
Smithtown, NY, 11787
Phone (631) 751-3000
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.5M
145,112 services
Medicare patients, 2024
1,671
Average age 76
Drug cost, 2024
$13.4M
2,865 prescriptions
Company payments, 2025
$73.66
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Noshir A Dacosta was code J1439 (injection, ferric carboxymaltose, 1 mg), 36,750 times for 47 patients. In total Noshir A Dacosta billed 145,112 services in 285 codes, and Medicare paid $2.5M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-01-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 36,750 | 47 | $0.87 | $32K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 8,700 | 17 | $2.06 | $18K |
| 88185 Surgical Pathology Examination | Office | 7,474 | 252 | $22.12 | $165K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 7,100 | 19 | $43.76 | $311K |
| J1756 Injection, iron sucrose, 1 mg | Office | 6,000 | 20 | $0.17 | $1,025 |
| J0897 Injection, denosumab, 1 mg | Office | 5,160 | 36 | $20.46 | $106K |
| 36415 Venipuncture Blood Collection | Office | 3,121 | 1,286 | $8.65 | $27K |
| 85025 Blood Count | Office | 3,107 | 1,295 | $7.61 | $24K |
| 80053 Clinical Chemistry | Office | 2,420 | 1,195 | $10.34 | $25K |
| 99214 Office E&M - Established | Office | 2,098 | 993 | $109.70 | $230K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,821 | 81 | $0.09 | $161 |
| 83615 Clinical Chemistry | Office | 1,653 | 890 | $5.91 | $9,775 |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 1,520 | 330 | $53.00 | $81K |
| 83735 Clinical Chemistry | Office | 1,437 | 784 | $6.57 | $9,441 |
| 84100 Clinical Chemistry | Office | 1,410 | 786 | $4.65 | $6,552 |
By year: 2022 $6.0M for 391,440 services; 2023 $3.9M for 219,828 services; 2024 $2.5M for 145,112 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 88185 Surgical Pathology Examination | 7,474 | 252 | $22.12 | $165K |
| 36415 Venipuncture Blood Collection | 3,121 | 1,286 | $8.65 | $27K |
| 85025 Blood Count | 3,107 | 1,295 | $7.61 | $24K |
| 80053 Clinical Chemistry | 2,420 | 1,195 | $10.34 | $25K |
| 83615 Clinical Chemistry | 1,653 | 890 | $5.91 | $9,775 |
| 83735 Clinical Chemistry | 1,437 | 784 | $6.57 | $9,441 |
| 84100 Clinical Chemistry | 1,410 | 786 | $4.65 | $6,552 |
| 82728 Clinical Chemistry | 1,376 | 789 | $13.34 | $18K |
| 84550 Clinical Chemistry | 1,374 | 753 | $4.43 | $6,087 |
| 82784 Immunoassay | 1,278 | 278 | $9.11 | $12K |
Medicare prescription drug claims, 2024
In 2024, the drug Noshir A Dacosta prescribed most often to Medicare patients was Aranesp (Darbepoetin Alfa In Polysorbat), with 250 prescriptions and refills. In total Noshir A Dacosta wrote 2,865 Medicare prescriptions that cost $13.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Aranesp Darbepoetin Alfa In Polysorbat | 250 | 253 | 57 | $834K |
| Anastrozole Generic | 156 | 403 | 64 | $2,953 |
| Akynzeo Fosnetupitant/Palonosetron | 132 | 133 | 23 | $132K |
| Procrit Epoetin Alfa | 107 | 107 | 12 | $140K |
| Fulvestrant Generic | 97 | 97 | 14 | $121K |
| Eliquis Apixaban | 94 | 128 | 26 | $73K |
| Somatuline Depot Lanreotide Acetate | 93 | 93 | 11 | $836K |
| Xgeva Denosumab | 77 | 87 | 17 | $240K |
| Lupron Depot Leuprolide Acetate | 77 | 99 | 12 | $195K |
| Octagam Immun Globg(Igg)/Malt/Iga Ov50 | 76 | 77 | Under 11 | $751K |
| Imbruvica Ibrutinib | 75 | 82 | Under 11 | $1.3M |
| Exemestane Generic | 64 | 142 | 22 | $15K |
| Keytruda Pembrolizumab | 54 | 54 | Under 11 | $610K |
| Ondansetron Odt Ondansetron | 52 | 52 | 35 | $632 |
| Xarelto Rivaroxaban | 50 | 82 | 15 | $45K |
Brand drugs: 1,834 claims; generic drugs: 1,031 claims; opioid claims: 30.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Noshir A Dacosta $73.66 ($73.66 in general payments such as food, travel and fees) from 2 companies. The largest payer was Genzyme Corporation with $45.89.
| Company | Payments | Amount |
|---|---|---|
| Genzyme Corporation SNY | 2 | $45.89 |
| Menarini Silicon Biosystems, Inc. | 1 | $27.77 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.